How did FLGT's revenue and expenses trends shift in Q4 2024?

Fulgent Genetics (FLGT) exhibited notable shifts in both revenue and expense trends during Q4 2024, reflecting strategic adjustments and operational changes within the company.

1. **Revenue Trends**:
- **Growth in Total Revenue**: FLGT's total revenue for Q4 2024 amounted to $76.21 million. This represents a significant increase of approximately 8.1% compared to the same quarter in the previous year, indicating a robust growth trajectory.
- **Alignment with Analyst Expectations**: The reported revenue was in line with analysts' estimates, with a slight variance of $76.09 million expected.
2. **Expense Trends**:
- **Expense Management**: The company's total expenses for Q4 2024 are not explicitly detailed in the available data. However, it is evident from the financial results that FLGT faced a GAAP loss of $5.89 million and a reported EPS loss of 19 cents for the quarter.
- **Non-GAAP Adjustments**: When considering non-GAAP adjustments, FLGT reported a non-GAAP income of $1.2 million, or $0.04 per share, and an adjusted EBITDA income of $0.8 million. This suggests that while GAAP expenses were high, the company managed to achieve profitability through non-GAAP adjustments.
3. **Comparative Analysis**: When comparing Q4 2024 to the previous quarter (Q3 2024), FLGT's revenue growth accelerated from a 9% year-over-year increase to a 14% growth in core revenue. This indicates a strengthening trend in revenue generation.
4. **Cash Flow and Financial Position**: FLGT ended 2024 with $828.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, representing a strong financial position. This liquidity is crucial for supporting the company's ongoing laboratory services and therapeutic development initiatives.

In conclusion, FLGT's revenue trends in Q4 2024 showed a strong growth trajectory, aligning with analyst expectations and reflecting effective revenue management. Despite GAAP losses, the company's strategic use of non-GAAP adjustments and its solid financial position underscore its resilience and potential for continued growth.